KR20230039701A - 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 7-(피페리딘-1-일)-4h-피리미도[1,2-b]피리다진-4-온 유도체 - Google Patents

무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 7-(피페리딘-1-일)-4h-피리미도[1,2-b]피리다진-4-온 유도체 Download PDF

Info

Publication number
KR20230039701A
KR20230039701A KR1020237005195A KR20237005195A KR20230039701A KR 20230039701 A KR20230039701 A KR 20230039701A KR 1020237005195 A KR1020237005195 A KR 1020237005195A KR 20237005195 A KR20237005195 A KR 20237005195A KR 20230039701 A KR20230039701 A KR 20230039701A
Authority
KR
South Korea
Prior art keywords
pyrimido
pyridazin
oxy
dihydrobenzo
dioxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020237005195A
Other languages
English (en)
Korean (ko)
Inventor
크레이그 더블유. 린드슬리
피. 제프리 콘
대런 더블유. 엔게스
앨리슨 알. 그레그로
카일라 제이. 템플
매들린 에프. 롱
안나 이. 링게트
로건 에이. 베이커
토마스 젠슨
Original Assignee
반더빌트유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반더빌트유니버시티 filed Critical 반더빌트유니버시티
Publication of KR20230039701A publication Critical patent/KR20230039701A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
KR1020237005195A 2020-07-15 2021-07-15 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 7-(피페리딘-1-일)-4h-피리미도[1,2-b]피리다진-4-온 유도체 Withdrawn KR20230039701A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063052085P 2020-07-15 2020-07-15
US63/052,085 2020-07-15
PCT/US2021/041836 WO2022015988A1 (en) 2020-07-15 2021-07-15 7-(piperidin-1-yl)-4h-pyrimido[1,2-b]pyridazin-4-one derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4

Publications (1)

Publication Number Publication Date
KR20230039701A true KR20230039701A (ko) 2023-03-21

Family

ID=77051222

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005195A Withdrawn KR20230039701A (ko) 2020-07-15 2021-07-15 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 7-(피페리딘-1-일)-4h-피리미도[1,2-b]피리다진-4-온 유도체

Country Status (11)

Country Link
US (3) US12331055B2 (https=)
EP (1) EP4182316A1 (https=)
JP (1) JP7766946B2 (https=)
KR (1) KR20230039701A (https=)
CN (1) CN116209446B (https=)
AU (1) AU2021308625A1 (https=)
BR (1) BR112023000760A2 (https=)
CA (1) CA3189217A1 (https=)
IL (1) IL299758B2 (https=)
MX (1) MX2023000580A (https=)
WO (1) WO2022015988A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024117795A1 (ko) 2022-12-02 2024-06-06 주식회사 엘지에너지솔루션 배터리 팩 및 그의 제조 방법

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4182316A1 (en) * 2020-07-15 2023-05-24 Vanderbilt University 7-(piperidin-1-yl)-4h-pyrimido[1,2-b]pyridazin-4-one derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2023141511A1 (en) * 2022-01-19 2023-07-27 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
AU2024259614A1 (en) 2023-04-18 2025-10-02 Vanderbilt University Thiazolopyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4
KR20260035912A (ko) * 2023-06-22 2026-03-13 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 양성 조절제
WO2025122733A1 (en) 2023-12-07 2025-06-12 Neumora Therapeutics, Inc. Crystalline forms of 7-((2r,4s)-4-((2,3-dihydrobenzo[b][1,4] dioxin-6-yl-2,2,3,3-d4)oxy)-2-methylpiperidin-1-yl)-8-methyl-4h-pyrimido[1,2-b]pyridazin -4-one
WO2026047494A1 (en) 2024-08-26 2026-03-05 Suven Life Sciences Limited 2-AMINO-PYRIMIDINE DERIVATIVES AS MUSCARINIC M4 RECEPTOR POSITIVE ALLOSTERIC MODULATORS (M4 PAMs)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156833B2 (en) * 2012-07-16 2015-10-13 Barry University, Inc. Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof
WO2014122474A1 (en) 2013-02-07 2014-08-14 Takeda Pharmaceutical Company Limited Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists
US10329289B2 (en) * 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2017107087A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 6, 7-dihydro-5h-pyrrolo [3, 4-b] pyridin-5-oneallosteric modulators of the m4 muscarinic acetylcholine receptor
US10961253B2 (en) * 2016-11-07 2021-03-30 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
WO2018112843A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) * 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
EP4182316A1 (en) * 2020-07-15 2023-05-24 Vanderbilt University 7-(piperidin-1-yl)-4h-pyrimido[1,2-b]pyridazin-4-one derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024117795A1 (ko) 2022-12-02 2024-06-06 주식회사 엘지에너지솔루션 배터리 팩 및 그의 제조 방법

Also Published As

Publication number Publication date
US11884676B2 (en) 2024-01-30
US20230286991A1 (en) 2023-09-14
EP4182316A1 (en) 2023-05-24
JP2023534803A (ja) 2023-08-14
IL299758A (en) 2023-03-01
IL299758B2 (en) 2026-04-01
BR112023000760A2 (pt) 2023-02-07
US12331055B2 (en) 2025-06-17
US20250263417A1 (en) 2025-08-21
CN116209446A (zh) 2023-06-02
US20230257381A1 (en) 2023-08-17
IL299758B1 (en) 2025-12-01
WO2022015988A1 (en) 2022-01-20
MX2023000580A (es) 2023-02-13
JP7766946B2 (ja) 2025-11-11
AU2021308625A1 (en) 2023-02-09
CN116209446B (zh) 2025-05-13
CA3189217A1 (en) 2022-01-20

Similar Documents

Publication Publication Date Title
JP7766946B2 (ja) ムスカリン性アセチルコリン受容体ｍ４の陽性アロステリック調節因子としての７－（ピペリジン－１－イル）－４ｈ－ピリミド［１，２－ｂ］ピリダジン－４－オン誘導体
EP3697759B1 (en) MUSCARINIC ACETYLCHOLINE RECEPTOR M4 ANTAGONISTS
RU2665462C2 (ru) Соединения 5-азаиндазола и способы их применения
US12006325B2 (en) Substituted furanopyrimidine compounds as PDE1 inhibitors
EP2991977B1 (en) C-linked heterocycloalkyl substituted pyrimidines and their uses
TW202515555A (zh) 作為pi3k抑制劑的苯并吡啶酮及苯并嘧啶酮
US20240342292A1 (en) Compounds for the Degradation of EGFR Kinase
JP7663968B2 (ja) Ｗｄｒ５阻害剤及び調節剤
WO2023064584A1 (en) 7,8-dihydro-5h-1,6-naphthyridine derivatives as positive allosteric modulators of the muscarinic acetylcholine receptor m4 for treating neurological and psychiatric disorders
EP4267569B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
CA3163933A1 (en) Antagonists of the muscarinic acetylcholine receptor m4
KR20240112343A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제
CA3180717A1 (en) Condensed substituted hydropyrroles as antagonists of the muscarinic acetylcholine receptor m4
WO2023141511A1 (en) Positive allosteric modulators of the muscarinic acetylcholine receptor m4
KR20250172652A (ko) 신경학적 및 정신의학적 장애의 치료에 유용한 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제로서의 1,6-나프티리딘 유도체
HK40036192B (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK40036192A (en) Substituted furanopyrimidine compounds as pde1 inhibitors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

B11 Application withdrawn

Free format text: ST27 STATUS EVENT CODE: N-1-6-B10-B11-NAP-PC1202 (AS PROVIDED BY THE NATIONAL OFFICE)

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202